Opportunity Information: Apply for PAR 21 210
This funding opportunity (PAR-21-210) is an NIH National Institute of Mental Health (NIMH) R01 grant solicitation focused on effectiveness trials for post-acute interventions and services aimed at improving longer-term outcomes for mental health conditions across the lifespan, including youth, adults, and older adults. It is a reissue of PAR-18-430 and is specifically positioned to support clinical trials in real-world or practice-relevant settings that can answer the practical question of whether a given post-acute therapeutic or service-delivery approach works when implemented under typical conditions. The emphasis is on the phase after an acute episode or an initial course of treatment, when many patients still experience residual symptoms, functional impairment, elevated relapse risk, or difficulty staying engaged with care.
The core purpose of the program is to fund statistically well-powered, definitive effectiveness trials of interventions that fit the post-acute stage of illness. In this context, "post-acute" generally means the period when a person has completed an initial acute treatment or has stabilized enough that the focus shifts from crisis management to sustaining gains and improving long-term functioning. The FOA highlights post-acute strategies such as consolidating and maintaining improvements achieved during initial treatment, addressing residual symptoms and ongoing impairment, preventing relapse or recurrence, supporting adherence to ongoing care plans, and promoting appropriate service use over time. NIMH is looking for interventions and service models that are not only clinically sensible for this stage, but also appropriately calibrated in intensity and burden, meaning they should be strong enough to help, while also being feasible and acceptable for patients, families, and service systems to sustain.
A major feature of the announcement is its encouragement to go beyond simple "does it work" questions by testing scientifically grounded hypotheses about why and for whom an intervention works. Applicants are encouraged to examine moderators, mediators, and mechanisms of action. In practical terms, this means a trial might be designed to identify which subgroups benefit most (moderators, such as baseline severity, comorbidities, social determinants, or treatment history), what intermediate changes explain downstream outcomes (mediators, such as improved coping skills, increased engagement, reduced stress exposure, better medication adherence), and what processes drive the effects (mechanisms of action, such as changes in reward processing, threat reactivity, sleep regulation, family communication patterns, or care coordination pathways). The expectation is that effectiveness testing is paired with a thoughtful plan to interpret outcomes in a way that can guide future implementation and optimization.
This FOA is for an R01 and is labeled "Clinical Trial Required," meaning applications are expected to include a clinical trial that evaluates an intervention or service approach in a rigorous way. NIMH is signaling that these should not be small exploratory studies; rather, they should be powered to provide a definitive answer about the intervention's effectiveness in the target population and setting. If a project is still at the stage where feasibility, tolerability, acceptability, safety, or only preliminary signals of effectiveness need to be established, NIMH points applicants to a companion R34 mechanism (noted in the text as currently TEMP-11235) that is intended for pilot effectiveness trials. In other words, the R01 is meant for the more mature, ready-to-test stage where the field needs clear evidence that can inform clinical practice and service delivery.
Eligibility is broad and includes many types of domestic applicants such as state, county, city, township, and special district governments; independent school districts; public and state-controlled and private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; and other eligible entities. The announcement also explicitly welcomes applications from a wide range of mission-driven and community-embedded organizations and institutions, including faith-based or community-based organizations, Hispanic-serving institutions, historically Black colleges and universities, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and Asian American, Native American, and Pacific Islander serving institutions. Importantly, foreign organizations and foreign institutions are eligible to apply, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by NIH policy, reflecting NIMH's openness to international collaboration or non-U.S. research settings when scientifically justified.
From an administrative standpoint, the opportunity is categorized as discretionary grant funding under the health activity category, with CFDA (now commonly referenced via Assistance Listing) number 93.242, and it is administered by the National Institutes of Health. The source listing indicates an original closing date of 2025-01-25. While the excerpt does not provide an award ceiling or expected number of awards, the central message is clear: NIMH wants robust, real-world effectiveness trials that test post-acute interventions and service strategies designed to protect gains from initial care, reduce relapse and ongoing impairment, and improve long-term clinical and functional outcomes, while also generating evidence about how, why, and for whom these approaches are most beneficial.Apply for PAR 21 210
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
- This funding opportunity was created on 2021-04-01.
- Applicants must submit their applications by 2025-01-25. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs) - NIH/NIMH PAR-21-210 (R01)
What is PAR-21-210?
PAR-21-210 is a funding opportunity announcement (FOA) from the National Institutes of Health (NIH), specifically the National Institute of Mental Health (NIMH). It uses the R01 mechanism and focuses on effectiveness trials of post-acute interventions and services intended to improve longer-term outcomes for mental health conditions across the lifespan.
Which NIH institute is sponsoring this opportunity?
The sponsoring institute is the National Institute of Mental Health (NIMH), under the National Institutes of Health (NIH).
What type of grant mechanism is this?
This FOA is for an NIH R01 research project grant.
Is a clinical trial required under this FOA?
Yes. The FOA is labeled "Clinical Trial Required," meaning the application is expected to include a clinical trial that rigorously evaluates an intervention or service approach.
What is the main goal of this FOA?
The core purpose is to fund statistically well-powered, definitive effectiveness trials of post-acute interventions and services in real-world or practice-relevant settings. The trials should address the practical question of whether an intervention works under typical conditions, and generate evidence that can inform clinical practice and service delivery.
What does "effectiveness trial" mean in the context of this announcement?
In this FOA, an effectiveness trial is a clinical trial conducted in real-world or practice-relevant settings to test whether a post-acute therapeutic or service-delivery approach works when implemented under typical conditions, rather than under tightly controlled, highly resourced research conditions.
What does "post-acute" mean in this funding opportunity?
"Post-acute" generally refers to the period after a person has completed an initial acute treatment or has stabilized enough that the focus shifts from crisis management to sustaining gains and improving long-term functioning. This phase often involves ongoing residual symptoms, functional impairment, elevated relapse risk, or challenges staying engaged with care.
Who is the target population for supported studies?
The FOA targets mental health conditions across the lifespan, including youth, adults, and older adults, with an emphasis on the post-acute stage of illness or care.
What kinds of outcomes is NIMH trying to improve through this program?
The FOA emphasizes improving longer-term outcomes after acute treatment, including sustaining clinical gains, reducing residual symptoms, improving functioning, lowering relapse or recurrence risk, supporting continued engagement with care, promoting adherence to care plans, and encouraging appropriate service use over time.
What kinds of post-acute strategies does the FOA highlight?
Examples of post-acute strategies highlighted include approaches to consolidate and maintain improvements from initial treatment, address residual symptoms and ongoing impairment, prevent relapse or recurrence, support adherence to ongoing plans, and promote appropriate service use across time.
What settings should the clinical trials be conducted in?
The FOA is positioned to support clinical trials in real-world or practice-relevant settings, where interventions and services can be tested under typical implementation conditions.
Does the FOA emphasize feasibility and sustainability of interventions?
Yes. NIMH is looking for interventions and service models that are appropriately calibrated in intensity and burden, meaning they should be feasible and acceptable for patients, families, and service systems to sustain, while still being strong enough to improve outcomes.
Is the FOA intended for small or exploratory studies?
No. The FOA indicates these should not be small exploratory studies; instead, they should be statistically well-powered, definitive effectiveness trials capable of providing clear answers about effectiveness in the target population and setting.
If a project is not ready for a definitive R01 effectiveness trial, what does NIMH suggest?
If the work is still focused on feasibility, tolerability, acceptability, safety, or only preliminary signals of effectiveness, the FOA points applicants to a companion R34 mechanism (noted in the text as TEMP-11235) intended for pilot effectiveness trials.
Does the FOA encourage studying why and for whom an intervention works?
Yes. A major feature of the announcement is encouraging applicants to go beyond "does it work" by testing scientifically grounded hypotheses about why and for whom an intervention works, including moderators, mediators, and mechanisms of action.
What are "moderators" in the context of this FOA?
Moderators are factors that help identify which subgroups benefit most from an intervention. The FOA provides examples such as baseline severity, comorbidities, social determinants, or treatment history.
What are "mediators" in the context of this FOA?
Mediators are intermediate changes that help explain downstream outcomes. The FOA provides examples such as improved coping skills, increased engagement, reduced stress exposure, better medication adherence, or other intermediate targets that connect the intervention to longer-term effects.
What are "mechanisms of action" as described in this FOA?
Mechanisms of action refer to processes that drive intervention effects. The FOA gives examples such as changes in reward processing, threat reactivity, sleep regulation, family communication patterns, or care coordination pathways.
What is the relationship of PAR-21-210 to earlier announcements?
PAR-21-210 is described as a reissue of PAR-18-430.
Who is eligible to apply?
Eligibility is broad. The FOA includes many types of domestic applicants (such as various levels of government, independent school districts, institutions of higher education, tribal governments and organizations, public housing authorities, nonprofits with or without 501(c)(3) status, for-profit organizations other than small businesses, and small businesses), as well as other eligible entities as specified in the announcement.
Are community-based or mission-driven organizations encouraged to apply?
Yes. The announcement explicitly welcomes applications from community-embedded and mission-driven organizations and institutions, including faith-based or community-based organizations and several categories of serving institutions (such as Hispanic-serving institutions, historically Black colleges and universities, and tribally controlled colleges and universities, among others listed).
Are foreign organizations eligible to apply?
Yes. The FOA states that foreign organizations and foreign institutions are eligible to apply.
Are non-U.S. components of U.S. organizations allowed?
Yes. The FOA indicates that non-U.S. components of U.S. organizations are eligible.
Are foreign components permitted under NIH policy?
Yes. The FOA states that foreign components are allowed as defined by NIH policy, supporting international collaboration or non-U.S. research settings when scientifically justified.
How is this funding opportunity categorized administratively?
The opportunity is categorized as discretionary grant funding under the health activity category.
What is the Assistance Listing (CFDA) number for this opportunity?
The Assistance Listing (formerly CFDA) number provided is 93.242.
When was the original closing date listed for this opportunity?
The source listing indicates an original closing date of 2025-01-25.
Does the excerpt provide an award ceiling or expected number of awards?
No. The excerpt does not provide an award ceiling or an expected number of awards.
What is the central emphasis of NIMH in this FOA?
The central emphasis is on robust, real-world effectiveness trials of post-acute interventions and service strategies designed to sustain gains from initial care, reduce relapse and ongoing impairment, improve long-term clinical and functional outcomes, and generate evidence about how, why, and for whom these approaches are beneficial.
Browse more opportunities from the same category: Health
Next opportunity: Alumni Opportunity Grants
Previous opportunity: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 21 210
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 21 210) also looked into and applied for these:
| Funding Opportunity |
|---|
| Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required) Apply for PAR 21 211 Funding Number: PAR 21 211 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed) Apply for PAR 21 196 Funding Number: PAR 21 196 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mentoring Networks to Enhance Diversity in NIDCD's Extramural Research Workforce (R25 Clinical Trial Not Allowed) Apply for PAR 21 185 Funding Number: PAR 21 185 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed) Apply for RFA RM 21 012 Funding Number: RFA RM 21 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Intramural - Extramural Collaboration for Drug Screening with Biofabricated 3-D Disease Tissue Models (UH2/UH3 Clinical Trial Not Allowed) Apply for RFA TR 21 015 Funding Number: RFA TR 21 015 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Radiation-Induced Immune Dysfunction (U01 Clinical Trial Not Allowed) Apply for RFA AI 21 019 Funding Number: RFA AI 21 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) Apply for PAR 21 197 Funding Number: PAR 21 197 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Short-Term Mentored Research Career Enhancement Award to Promote Diversity (K18 No Independent Clinical Trials) Apply for PA 21 214 Funding Number: PA 21 214 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed) Apply for RFA RM 21 020 Funding Number: RFA RM 21 020 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Limited Competition: Clinical and Translational Science Awards (CTSA) Consortium-Wide Centers: Resources for Rapid Demonstration and Dissemination (U24 Clinical Trials Not Allowed) Apply for PAR 21 203 Funding Number: PAR 21 203 Agency: National Institutes of Health Category: Health Funding Amount: $3,000,000 |
| Research Experiences to Enhance Clinician-Scientists' Participation in NIDCDs Research (R25 Clinical Trial Not Allowed) Apply for PAR 21 188 Funding Number: PAR 21 188 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional) Apply for RFA RM 21 015 Funding Number: RFA RM 21 015 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| NINDS Program Project Grant (P01 Clinical Trial Optional) Apply for PAR 21 181 Funding Number: PAR 21 181 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimers Disease and Related Dementias (AD/ADRD) (R01 Clinical Trial Optional) Apply for PAR 21 207 Funding Number: PAR 21 207 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimers Disease and Related Dementias (AD/ADRD) (R61/R33 Clinical Trial Required) Apply for RFA AG 22 016 Funding Number: RFA AG 22 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed) Apply for PAR 21 152 Funding Number: PAR 21 152 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding HIV Reservoir Dynamics (P01, Clinical Trial Not Allowed) Apply for RFA AI 21 013 Funding Number: RFA AI 21 013 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required) Apply for PAR 21 153 Funding Number: PAR 21 153 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA AG 21 035 Funding Number: RFA AG 21 035 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| National Institute of General Medical Sciences (NIGMS) Bridges to the Doctorate (T32) Apply for PAR 21 198 Funding Number: PAR 21 198 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 21 210", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.